# Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Study · id `cardio:ct-nct01918332` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01918332](<https://clinicaltrials.gov/study/NCT01918332>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01918332

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT01918332. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-12-15.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Results first posted: 2014-12-15 (ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01918332, source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01918332-2014-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
- Condition: Hypertension,
- Condition: Hyperlipidemia
- Intervention (Drug): Valsartan 160mg
- Intervention (Drug): Rosuvastatin 20mg
- Intervention (Drug): Valsartan 160mg placebo
- Intervention (Drug): Rosuvastatin 20mg placebo
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: d2868cc583d64ce8069be3b4af0d5c27a0a3e6b0dae2d64af45ce32b6b184510
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
